Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Drugs Chief: Vouchers Put FDA In 'Distasteful' Situation

This article was originally published in Scrip

Executive Summary

Just as the House Oversight and Government Reform Committee decided it was time to look into whether the FDA's priority review vouchers (PRV) are being exploited, lawmakers on Capitol Hill also felt it was necessary to keep the specific portion of the program going for another six months that awards the "golden tickets" to firms that win approval of rare pediatric disease medicines – even though high-ranking US regulators would like to see it end.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts